Table 2 Mendelian Randomization estimates of Probucol’s effect on Behçet’s disease.
Exposure | Outcome | Nsnp | Method | MR | Heterogeneity | Horizontal pleiotropy | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug_OR (95%CI) | P value | I2 (%) | Cochran’s Q | P-value | Egger intercept | SE | P-value | MR-PRESSO global test p | ||||
ABCA1 inhibitor | Behcet’s disease | 30 | MR Egger | 0.5648 (0.1006–3.1702) | 0.5216 | 0 | 23.4880 | 0.7083 | 0.0172 | 0.1097 | 0.8764 | 0.7610 |
Weighted median | 0.4233 (0.1867–0.96) | 0.0396 | – | – | – | – | – | – | 0.7610 | |||
Inverse variance weighted | 0.4957 (0.283–0.8681) | 0.0141 | 0 | 23.5126 | 0.7526 | – | – | – | 0.7610 | |||
Simple mode | 0.4539 (0.1285–1.6032) | 0.2297 | – | – | – | – | – | – | 0.7610 | |||
Weighted mode | 0.4207 (0.1707–1.0369) | 0.0700 | – | – | – | – | – | – | 0.7610 |